Skip to main content

4D pharma PLC (LBPS)

NASDAQ: LBPS · Delayed Price · USD
7.45
+0.28 (3.91%)
After-hours:Sep 21, 2021 5:07 PM EDT
7.17
0.24 (3.46%)
At close: Sep 21, 4:00 PM
Market Cap167.10M
Revenue (ttm)690,000
Net Income (ttm)-30.50M
Shares Out22.54M
EPS (ttm)-2.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,332
Open7.44
Previous Close6.93
Day's Range7.04 - 7.50
52-Week Range6.93 - 15.50
Beta2.92
Analystsn/a
Price Target37.50 (+423.0%)
Est. Earnings Daten/a

About LBPS

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multip...

IndustryBiotechnology
Founded2014
CEODuncan Peyton
Employees92
Stock ExchangeNASDAQ
Ticker SymbolLBPS
Full Company Profile

Financial Performance

In 2020, 4D pharma's revenue was $690,000, an increase of 156.51% compared to the previous year's $269,000. Losses were -$30.50 million, 0.53% more than in 2019.

Financial Statements

News

4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

6 days ago - Business Wire

4D pharma to Participate in Upcoming Virtual Investor Conferences in September

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 week ago - Business Wire

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 month ago - Business Wire

4D pharma Announces $30 Million Credit Facility with Oxford Finance

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 month ago - Business Wire

4D pharma Announces Passing of Chief Financial Officer John Beck

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 month ago - Business Wire

4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

2 months ago - Business Wire

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

2 months ago - Business Wire

4D pharma to Present at the Microbiome Movement Drug Development Summit

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

2 months ago - Business Wire

4D pharma To Stop Testing Asthma Med in COVID-19 Patients

4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma. Following the completion of en...

3 months ago - Benzinga

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provi...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

3 months ago - Business Wire

4D pharma PLC has completed recruitment for first part of its phase I/II asthma trial

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said had finished recruitment of the first part of its phase I/II evaluation of MRx-4DP0004 in patients with partly controlled asthma. In all, 30 people with the co...

3 months ago - Proactive Investors

4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate

4D pharma plc (NASDAQ: LBPS) has announced additional positive data from its completed Phase 2 trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (...

3 months ago - Benzinga

4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syn...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

3 months ago - Business Wire

4D pharma "encouraged" after additional analysis of IBS drug data

4D pharma PLC (LON:DDDD NASDAQ:LBPS) said it has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irrita...

3 months ago - Proactive Investors

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

4 months ago - Business Wire

4D pharma Collaborates With Parkinson's UK to Establish Patient Advisory Board

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

5 months ago - Business Wire

4D Pharma teams up with Parkinson's UK

4D Pharma PLC (LON:DDDD; NASDAQ:LBPS) said it will collaborate with Parkinson's UK as it continues to advance a drug that treats neurodegenerative conditions such as Parkinson's into clinical trials. It...

5 months ago - Proactive Investors

4D pharma PLC teams up with Parkinson's UK

4D pharma PLC (LON:DDDD; NASDAQ:LBPS) said it will collaborate with Parkinson's UK as it continues to advance into clinical trials a drug that treats neurodegenerative conditions such as Parkinson's. It...

5 months ago - Proactive Investors

Final Results for the year ended 31 December 2020

Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the developm...

5 months ago - GlobeNewsWire

4D pharma highlights significant progress made in 2020

4D pharma PLC (LON:DDD, NASDAQ:LBPS) hailed 2020 as a “transformational year” for the company. In its full-year results statement, the company listed the publication of the first proof-of-concept data f...

5 months ago - Proactive Investors

Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on...

LEEDS, United Kingdom--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug ...

5 months ago - Business Wire

4D pharma Announces Completion of Merger With Longevity Acquisition Corporation

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel...

5 months ago - Business Wire

Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders

NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its speci...

6 months ago - PRNewsWire

4D Pharma Announces Private Placement

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived...

6 months ago - Business Wire

4D Pharma to Present at Upcoming Investor Conferences in March

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, t...

6 months ago - Business Wire